November 6, 2024 07:00 AM EST

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

Kyle LaHucik

Senior Reporter

SAN ANTONIO — It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field’s next …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

‘We’re good’ on weight loss: Bio­phar­mas turn to mus­cle with new obe­si­ty drugs

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?